Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search
Back to Resource Library

Eswatini Pre-Exposure Prophylaxis Implementation Guidelines, 2025

10 July 2026

These implementation guidelines, developed by Eswatini’s Ministry of Health in 2025, can be used to support delivery of PrEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).

Topic(s): Normative Guidance/Policies

Product(s): Cabotegravir, Dapivirine Vaginal Ring, Injectable Prep, Lenacapavir, Oral PrEP

Region(s): Sub-Saharan Africa

Format(s): Report

Countries: Eswatini

Source(s): Eswatini Ministry of Health

Type: Document

Download

Featured Resources

Document

Mozambique Guidelines for Combined Biomedical Prevention of HIV, STIs, and Viral Hepatitis, 2025

These clinical guidelines, developed by Mozambique’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
Document

Lesotho Addendum to HIV Prevention, Treatment, and Care Guidelines, 2026

These clinical guidelines, developed by Lesotho’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
Document

Introduction and Scale‑up of the Dapivirine Vaginal Ring, Long‑Acting Injectable Cabotegravir and Lenacapavir for HIV Prevention in Eswatini Implementation Plan Version II, 2025-2030

This PrEP Implementation Plan, developed by Eswatini’s Ministry of Health, is a strategic roadmap to guide Eswatini’s scale-up of HIV prevention. It translates global WHO guidance and national commitments into actionable steps, ensuring that oral PrEP, the dapivirine vaginal ring, and long-acting injectables such as cabotegravir and lenacapavir are introduced in a coordinated, evidence-based way.…
External Link

Long-Acting Injectable Cabotegravir Use and Persistence Over Two Years

This article from JAMA Network Open explores levels of cabotegravir for PrEP uptake and persistence in the US since approval by the US Food and Drug Administration in December 2021.
External Link

Drivers of Vertical HIV Transmission in Sub-Saharan Africa and the Impact and Cost-Effectiveness of Targeted and Universal Lenacapavir Pre-Exposure Prophylaxis

This article from Journal of the International AIDS Society evaluates drivers of vertical transmission in Sub Saharan Africa and assesses the impact and cost-effectiveness of lenacapavir for PrEP amongst pregnant and lactating people without HIV.
External Link

An Advocates’ Checklist for Lenacapavir for PrEP Introduction

The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers accelerate equitable access to LEN for PrEP. The checklist is designed to support faster, community-centered rollout ahead of broader generic availability in 2027.
External Link

Long-Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A cost-effectiveness analysis

This article from Journal of the International AIDS Society assesses the potential clinical and economic impact of offering injectable cabotegravir or lenacapavir to gay and bisexual men who have sex with men and transgender women with high vulnerability to HIV acquisition in Brazil and determines the maximum cost at which they would be cost-effective.
Document

LEN Rollout Resources and Tools

The resources listed in this document, alongside insights drawn from the report Getting PrEP Rollout Right This Time, can support countries in the early stages of LEN planning. These tools are being disseminated as part of a coordinated effort between AVAC, CHAI, CIFF, the Global Fund, PEPFAR, PSI, Unitaid, Wits RHI, and WHO under the…
Document

Kenya Integrated Guidelines for Prevention, Treatment and Management of HIV, Sexually Transmitted Infections and Viral Hepatitis, 2026

These clinical guidelines, developed by Kenya’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
External Link

Global PrEP Tracker

Last update: April 2026 Visit data.prepwatch.org for a dynamic map-based tool to explore trends in PrEP use globally, including by country, product, and time period. Comprehensive datasets are available to download by clicking “download data” in the upper righthand corner. For any questions, contact [email protected]. Introduction to the Global PrEP Tracker